Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial

BACKGROUND: Voriconazole is a first-line agent for the prevention and treatment of a number of invasive fungal diseases. Relatively little is known about the relationship between drug exposure and the prevention of invasive fungal infections. PATIENTS AND METHODS: A pharmacokinetic–pharmacodynamic s...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Antimicrob Chemother
Auteurs principaux: Hope, William W., Walsh, Thomas J., Goodwin, Joanne, Peloquin, Charles A., Howard, Alan, Kurtzberg, Joanne, Mendizabal, Alan, Confer, Dennis L., Bulitta, Jürgen, Baden, Lindsey R., Neely, Michael N., Wingard, John R.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2016
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4954923/
https://ncbi.nlm.nih.gov/pubmed/27121401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkw127
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires